)
ReLabLink: A marketplace for used laboratory equipment and consumables
There's a second-hand market for everything from sailboats to old vases. So why not for laboratory equipment? Lab lead Emmanuelle Benard saw the need and created a new service.
New dPCR core facility in ShareLab
Published: 17 April 2024
Text: ShareLab
Photo: Sigurd Reistad Klæva
)
On a mission to establish dPCR as a mainstream technology in the Norwegian biotech industry, QIAGEN has selected ShareLab as the base for a new “industrial core facility”.
Here anyone wanting to test or use dPCR can get access to QIAGEN’s state-of-the-art QIAcuty instruments. Scientists from companies and institutes can come to ShareLab to receive training and demos, run tests, or run both small and large projects on these. In addition to the instruments, they will also find kits and materials here, plus the expertise they need to set up their experiments and procedures and to evaluate and improve their results.
“This is a strategic partnership”, says Christine Vimo, Senior Account Manager at QIAGEN.
“ShareLab’s attractive location and facilities, their sharing-economy concept, and their exciting community of cutting-edge biotech startups, makes the perfect environment for us to establish our dPCR core facility. With this, QIAGEN will be able to make dPCR capabilities and tools available to many more Norwegian companies and scientists than we previously thought possible. We are very excited to be here!”
)
Christine Vimo, Senior Account Manager at QIAGEN (middle) together with ShareLab's Marius Øgaard and Samrawit M. Gebretensaie.
QIAGEN’s innovative dPCR solutions provide a whole new level of sensitivity and precision in nucleic acid detection and quantification.
“At ShareLab we are constantly working to improve and expand the equipment in our lab, so that we can always offer the best tools to our members. This new partnership goes far beyond that!” says Marius Øgaard, Partner at ShareLab.
“By establishing this new core facility together, QIAGEN and ShareLab are reaching out with an attractive new offering to anyone in Norway who is interested in upgrading from qPCR/PCR to dPCR. Even if it is a relatively simple solution to implement, we believe this can be a stepping stone project for the whole industry.”
Related articles
)
Fenris Bio: Aiming to challenge current Crohn’s Disease treatment
Fenris Bio was founded on the basis of an idea without experimental data, but with investors willing to take the risk. Now, the ShareLab company is working to test the first candidates for a new biological medicine for Crohn’s disease.
)
Health Innovation: “Encouraging to see more companies emerging from OUS”
As almost the closest neighbor to Oslo University Hospital (OUS), it is a short walk for researchers and clinicians to the innovation ecosystem at Forskningsparken. In the ShareLab incubator, there is now a long list of OUS-based companies on the membership roster.
)
Maria Vistnes at Klyv Therapeutics: From lab coat to the executive chair
After many years as a cardiologist and researcher, Maria Vistnes has traded hospital corridors and academia for a day-to-day life as a founder in her own biotechnology company, Klyv Therapeutics. The driving force is not a desire to leave the medical profession, but a conviction that the most effective way to help patients is to develop a new treatment.
)
)
Cellmover: Norwegian biotechnology success paves the way for new cancer treatment
Cellmover is now making great strides in developing next-generation cancer therapies. The company has recently secured funding through the Eurostars program, and CSO Miriam Aarsund Larsen has been named one of Norway's 50 leading women in technology. How did she transition from researcher to leader, and what is driving Cellmover forward?